Application | Comment | Organism |
---|---|---|
medicine | coadministration of DPP-4 inhibitor vildagliptin with either glyburide or pioglitazone in patients with diabetes type 2 improves postprandial glycemic control | Homo sapiens |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
vildagliptin | more than 90% inhibition within 30 min of administration of vildagliptin and glyburide, while glyburide alone has no effect on DPP-4 activity | Homo sapiens |
Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
---|---|---|---|---|---|---|
glucagon-like peptide 1 + H2O | Homo sapiens | - |
? | - |
? |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
blood plasma | - |
Homo sapiens | - |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
glucagon-like peptide 1 + H2O | - |
Homo sapiens | ? | - |
? | |
Gly-L-Pro-7-amido-4-methylcoumarin + H2O | - |
Homo sapiens | Gly-L-Pro + 7-amino-4-methylcoumarin | - |
? |
Synonyms | Comment | Organism |
---|---|---|
dipeptidyl peptidase IV | - |
Homo sapiens |
DPP-4 | - |
Homo sapiens |